Rhythm Pharmaceuticals Inc.(简称:Rhythm Pharmaceuticals)近日公布了其二期临床试验的初步数据。该试验结果显示,实验性药物Rm-718在治疗获得性下丘脑肥胖方面,成功呈现出了积极的疗效信号。这一发现为相关领域的治疗探索带来了令人鼓舞的进展。
Rhythm Pharmaceuticals Inc.(简称:Rhythm Pharmaceuticals)近日公布了其二期临床试验的初步数据。该试验结果显示,实验性药物Rm-718在治疗获得性下丘脑肥胖方面,成功呈现出了积极的疗效信号。这一发现为相关领域的治疗探索带来了令人鼓舞的进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.